<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Am J Physiol Gastrointest Liver Physiol</journal-id>
<journal-id journal-id-type="iso-abbrev">Am. J. Physiol. Gastrointest. Liver Physiol</journal-id>
<journal-id journal-id-type="pmc">ajpgi</journal-id>
<journal-id journal-id-type="publisher-id">Am J Physiol Gastrointest Liver Physiol</journal-id>
<journal-id journal-id-type="publisher-id">AJPGI</journal-id>
<journal-title-group>
<journal-title>American Journal of Physiology - Gastrointestinal and Liver Physiology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0193-1857</issn>
<issn pub-type="epub">1522-1547</issn>
<publisher>
<publisher-name>American Physiological Society</publisher-name>
<publisher-loc>Bethesda, MD</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29494209</article-id>
<article-id pub-id-type="pmc">6032063</article-id>
<article-id pub-id-type="publisher-id">GI-00026-2018</article-id>
<article-id pub-id-type="publisher-manuscript">GI-00026-2018</article-id>
<article-id pub-id-type="doi">10.1152/ajpgi.00026.2018</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
<series-title>The Gut-Liver Axis</series-title>
</article-categories>
<title-group>
<article-title>Biliverdin reductase and bilirubin in hepatic disease</article-title>
<alt-title alt-title-type="running-head">BILIRUBIN AND LIVER DISEASE</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-8393-2967</contrib-id>
<name>
<surname>Weaver</surname>
<given-names>Lauren</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hamoud</surname>
<given-names>Abdul-rizaq</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-8359-4008</contrib-id>
<name>
<surname>Stec</surname>
<given-names>David E.</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-7599-1529</contrib-id>
<name>
<surname>Hinds</surname>
<given-names>Terry D.</given-names>
<suffix>Jr.</suffix>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<aff id="aff1"><sup>1</sup>Department of Physiology and Pharmacology, Center for Hypertension and Personalized Medicine, <institution>University of Toledo College of Medicine</institution>, <addr-line>Toledo, Ohio</addr-line></aff>
<aff id="aff2"><sup>2</sup>Department of Physiology and Biophysics, Mississippi Center for Obesity Research, <institution>University of Mississippi Medical Center</institution>, <addr-line>Jackson, Mississippi</addr-line></aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Address for reprint requests and other correspondence: T. D. Hinds, Jr., Dept. of Physiology and Pharmacology, 3000 Arlington Ave., Mailstop 1008, Univ. of Toledo College of Medicine, Toledo, OH 43614 (e-mail: <email>terry.hinds@utoledo.edu</email>).</corresp>
</author-notes>
<pub-date pub-type="ppub">
<day>1</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>1</day>
<month>3</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>6</month>
<year>2019</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>314</volume>
<issue>6</issue>
<fpage>G668</fpage>
<lpage>G676</lpage>
<history>
<date date-type="received">
<day>19</day>
<month>1</month>
<year>2018</year>
</date>
<date date-type="rev-recd">
<day>22</day>
<month>2</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>2</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 the American Physiological Society</copyright-statement>
<copyright-year>2018</copyright-year>
<copyright-holder>American Physiological Society</copyright-holder>
</permissions>
<self-uri content-type="pdf" xlink:href="ajpgi.00026.2018.pdf"></self-uri>
<abstract>
<p>The buildup of fat in the liver (hepatic steatosis) is the first step in a series of incidents that may drive hepatic disease. Obesity is the leading cause of nonalcoholic fatty liver disease (NAFLD), in which hepatic steatosis progresses to liver disease. Chronic alcohol exposure also induces fat accumulation in the liver and shares numerous similarities to obesity-induced NAFLD. Regardless of whether hepatic steatosis is due to obesity or long-term alcohol use, it still may lead to hepatic fibrosis, cirrhosis, or possibly hepatocellular carcinoma. The antioxidant bilirubin and the enzyme that generates it, biliverdin reductase A (BVRA), are components of the heme catabolic pathway that have been shown to reduce hepatic steatosis. This review discusses the roles for bilirubin and BVRA in the prevention of steatosis, their functions in the later stages of liver disease, and their potential therapeutic application.</p>
</abstract>
<kwd-group>
<kwd>ALD</kwd>
<x xml:space="preserve">; </x>
<kwd>bilirubin</kwd>
<x xml:space="preserve">; </x>
<kwd>BVRA</kwd>
<x xml:space="preserve">; </x>
<kwd>fatty liver disease</kwd>
<x xml:space="preserve">; </x>
<kwd>fibrosis</kwd>
<x xml:space="preserve">; </x>
<kwd>NAFLD</kwd>
<x xml:space="preserve">; </x>
<kwd>PPARα</kwd>
</kwd-group>
<funding-group>
<award-group id="award1">
<funding-source>
<named-content content-type="funder-name">HHS | NIH | National Heart, Lung, and Blood Institute (NHBLI)</named-content>
<named-content content-type="funder-identifier">10.13039/100000050</named-content>
</funding-source>
<award-id>K01HL-125445</award-id>
<award-id>PO1HL-051971</award-id>
<award-id>HL088421</award-id>
</award-group>
<award-group id="award2">
<funding-source>
<named-content content-type="funder-name">HHS | NIH | National Center on Minority Health and Health Disparities (NCMHD)</named-content>
<named-content content-type="funder-identifier">10.13039/100000096</named-content>
</funding-source>
<award-id>L32MD009154</award-id>
</award-group>
<award-group id="award3">
<funding-source>
<named-content content-type="funder-name">HHS | NIH | National Institute of General Medical Sciences (NIGMS)</named-content>
<named-content content-type="funder-identifier">10.13039/100000057</named-content>
</funding-source>
<award-id>P20GM-104357</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>Call for Papers</meta-name>
<meta-value>True</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>